Objectives We sought to characterize our experience with SLN biopsy in patients with vulvar cancer, focusing on the modality of SLN detection.
Methods We performed a retrospective analysis of patients who underwent inguinofemoral SLN biopsy for vulvar cancer at Memorial Sloan Kettering Cancer Center from 1/1/2000–4/1/2019. An “at-risk groin” was defined as the inguinofemoral lymph nodes from either the right or left groin for which SLN biopsy was performed. Pearson’s Chi-Squared test was used for comparison of categorical variables.
Results 160 patients were included, representing 265 at-risk groins. Demographic and pathologic features are summarized in the table 1. Patients underwent mapping with a combination of Technicium-99 radiocolloid injection (TC-99), blue dye injection, or near-infrared imaging with indocyanine green (ICG) injection. SLN detection rate, irrespective of modality, was 96.2%. TC-99 + Blue dye detected SLNs in 91.8% of groins, and TC-99 + ICG detected SLNs in 100% of groins (p = 0.157). The use of ICG alone resulted in an SLN detection rate of 96.3% (26/27). Among the 110 groins that underwent mapping with TC-99 and blue dye, 4 patients mapped with TC-99 alone (3.6%). Among the 96 groins that underwent mapping with TC-99 and ICG, 14 mapped with ICG alone (14.6%).
Conclusions The use of ICG for inguinofemoral SLN mapping has increased over the past decade and is associated with the highest rates of SLN mapping of any modality.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.